Wednesday, March 26, 2014

Barclays Initiates Coverage on Kate Spade & Co (KATE)

Barclays was launched coverage on shares of Kate Spade & Co (NASDAQ: KATE) in a report issued on Wednesday, Analyst Ratings Network. com logs. The firm issued an weighty rating and a $50. 00 guide price on the stock.

Juicy Couture iPhone 5 Case Pink

Shares to do with Kate Spade & Co (NASDAQ: KATE) traded down 0. 82% on Tuesday, hitting $39. 82. The stock had a trading variety of 350, 492 shares. Kate Spade & Co has a 1-year reduced of $18. 13 and a 12 months high of $40. 45. The share has a 50-day moving average to do with $32. 88 and a 200-day working average of $29. 82. Flexalite has a market cap of $4. 914 billion and a price-to-earnings rate of 68. 05.

A number of other choose have also recently commented on KATE. Analysts at Citigroup Inc. better shares of Kate Spade as well as Co from a neutral rating even to a buy rating in a research record on Monday, March 3rd. On an individual basis, analysts at Telsey Advisory Bunch raised their price target not to mention shares of Kate Spade as well as Co from $38. 00 to assist you to $40. 00 in a research record on Wednesday, February 26th. Now they have a not rated rating towards the stock. Finally, analysts at Monness Crespi & Hardt downgraded explains of Kate Spade & C from a buy rating to a fairly neutral rating in a research note not to mention Wednesday, February 26th. They taken into consideration that the move was a valuation call us at.

Kate Spade & Co, currently Fifth & Pacific Companies Incorporation, designs and markets a some sort of of retail-based, premium brands, inclusive of JUICY COUTURE, KATE SPADE and even LUCKY BRAND.

To view Barclays’ traditional report, visit Barclays’ official world-wide-web page.

Get Analysts' Upgrades and Downgrades via Email - Stay on top to do with analysts' coverage with Analyst Score Network's FREE daily email newsletter that provides another concise list of analysts' upgrades and even downgrades. Click here to register now.

No comments:

Post a Comment